0001144204-12-027411.txt : 20120510 0001144204-12-027411.hdr.sgml : 20120510 20120510102258 ACCESSION NUMBER: 0001144204-12-027411 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120504 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20120510 DATE AS OF CHANGE: 20120510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30975 FILM NUMBER: 12828175 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 8-K 1 v312657_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 4, 2012

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-30975		911789357
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

12325 Emmet Street, Omaha, Nebraska		68164
(Address of principal executive offices)		(Zip Code)

(402) 452-5400

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 4, 2012, Transgenomic, Inc. (the “Company”) provided written notice to CFO Systems, LLC that the Company’s engagement contract with CFO Systems, LLC (the “CFO Systems Agreement”) is terminated effective June 3, 2012. Under the CFO Systems Agreement, Brett L. Frevert, Managing Director of CFO Systems, LLC, has been serving as the Company’s interim Chief Financial Officer (Principal Financial Officer). In connection with the termination of the CFO Systems Agreement, Mr. Frevert will cease his role as the Company’s Chief Financial Officer effective June 3, 2012. Beginning June 3, 2012, Mr. Craig J. Tuttle, the Company’s Chief Executive Officer, will serve as the Company’s interim Chief Financial Officer (Principal Financial Officer) while the Company completes a search for a permanent Chief Financial Officer. The Company expects to announce the hiring of a new Chief Financial Officer in the near future.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 10, 2012

TRANSGENOMIC, INC.

By: /s/ Craig J. Tuttle

Craig J. Tuttle

President and Chief Executive Officer